Carole Huntsman - 20 Nov 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Chief Commercial Officer
Signature
/s/ Brian J. Lynch
Issuer symbol
MDGL
Transactions as of
20 Nov 2023
Net transactions value
$0
Form type
4
Filing time
22 Nov 2023, 17:02:08 UTC
Next filing
25 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Award $0 +7,834 $0.000000 7,834 20 Nov 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Award $0 +10,077 $0.000000 10,077 20 Nov 2023 Common Stock 10,077 $190.05 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units, which vest as to 25% of the shares on each of November 20, 2024, November 20, 2025, November 20, 2026 and November 20, 2027, provided the Reporting Person continues in service with the Issuer on each such date.
F2 The option vests as to 25% of the shares on the first anniversary of the date of grant (November 20, 2024) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

Remarks:

** As attorney-in-fact for Reporting Person